nelivaptan
Small moleculeexperimental
Nelivaptan (INN) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype. The drug had entered clinical trials for treatment of anxiety and depression. In July 2008, Sanofi-Aventis announced that further development of this drug had been halted. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2006 (NCT00358631)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Vasopressin V1b receptorANTAGONIST
AVPR1B antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(S(=O)(=O)N2C(=O)[C@@](c3ccccc3OC)(N3C[C@H](O)C[C@H]3C(=O)N(C)C)c3cc(Cl)ccc32)c(OC)c1- Mol. weight
- 630.12 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNelivaptan ↗
- ChEMBLCHEMBL582857 ↗
Also known as
- 1-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1h-indol-3-yl)-4-hydroxy-n,n-dimethyl-2-pyrrolidinecarboxamide
- nelivaptan
- nelivaptan
- nelivaptan
- sr-149415
- sr-149415
- ssr149415
- ssr149415
- ssr149415
- ssr 149415
- ssr-149415
- ssr-149415
- ssr-149415
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01606384 | Phase 2 | Dec 1, 2006 | Sanofi |
| NCT00361491 | Phase 2 | Aug 1, 2006 | Sanofi |
| NCT00374166 | Phase 2 | Aug 1, 2006 | Sanofi |
| NCT00358631 | Phase 2 | Jul 1, 2006 | Sanofi |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 4 | 4 | 1 | 2006 |
1 organizations
Page 1 / 1